Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 11/20 | 0.44 |
| ▸ | CTSK | P43235 | 10/20 | 0.44 |
| ▸ | TACR1 | P25103 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | GSTP1 | P09211 | 1/20 | 0.41 |
| ▸ | GSTM2 | P28161 | 1/20 | 0.41 |
| ▸ | CTSB | P07858 | 2/20 | 0.40 |
| ▸ | CTSL | P07711 | 2/20 | 0.40 |
| ▸ | ACE | P12821 | 1/20 | 0.39 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.39 |
| ▸ | AAK1 | Q2M2I8 | 1/20 | 0.39 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL539351 | 1.00 | KLK5 (0.46) | KLK5CTSSCTSKTACR1ALDH1A1 | |
| SCHEMBL4245453 | 1.00 | KLK5 (0.46) | KLK5CTSSCTSKTACR1ALDH1A1 | |
| SCHEMBL3376657 | 0.89 | ACE (0.50) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL539422 | 0.89 | ACE (0.50) | CTSSCTSKCTSBCTSLACE | |
| SCHEMBL16065010 | 0.88 | CTSS (0.44) | CTSSCTSKALDH1A1MAPTCTSB | |
| SCHEMBL28989690 | 0.88 | CTSS (0.44) | CTSSCTSKALDH1A1MAPTCTSB | |
| SCHEMBL8393733 | 0.86 | KLK5 (0.49) | KLK5CTSSCTSKTACR1GSTP1 | |
| SCHEMBL14164209 | 0.86 | KLK5 (0.47) | KLK5CTSSCTSKTACR1ALDH1A1 | |
| SCHEMBL20397721 | 0.85 | KLK5 (0.46) | KLK5CTSSCTSKTACR1GSTP1 | |
| SCHEMBL4244223 | 0.84 | KLK5 (0.45) | KLK5CTSSCTSKTACR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9175003-B2 | Substituted azoanthracene derivatives and intermediates for preparation thereof | VTV THERAPEUTICS LLC (US) | 2015-11-03 | — | — | US | disclosed |
| EP-2413693-B1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | VTV THERAPEUTICS LLC (US) | 2015-09-09 | — | — | EP | disclosed |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | VTV THERAPEUTICS LLC | 2015-05-28 | — | — | US | disclosed |
| US-8987295-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, LLC (US) | 2015-03-24 | — | — | US | disclosed |
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | TRANSTECH PHARMA, INC. (US) | 2013-04-18 | — | — | US | disclosed |
| US-8383644-B2 | Substituted azoanthracene derivatives, pharmaceutical compositions, and methods of use thereof | TRANSTECH PHARMA, INC. (US) | 2013-02-26 | — | — | US | disclosed |
| EP-2413693-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TransTech Pharma, Inc (US) | 2012-02-08 | — | — | EP | disclosed |
| US-20110160198-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | HIGH POINT PHARMACEUTICALS, LLC (US) | 2011-06-30 | — | — | US | disclosed |
| WO-2010114824-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | TRANSTECH PHARMA INC (US) | 2010-10-07 | — | — | WO | disclosed |
| US-20090124654-A1 | Aryl and Heteroaryl Compounds, Compositions, Methods of Use | TRANSTECH PHARMA, INC. | 2009-05-14 | — | — | US | disclosed |
| EP-1888566-A1 | 2-[(ISOQUINOLIN-3-CARBONYL)AMINO]-PROPIONIC ACID DERIVATIVES AS INHIBITORS OF FACTORS XI AND IX FOR THE TREATMENT OF THROMBOSIS | Transtech Pharma, Inc. (US) | 2008-02-20 | — | — | EP | disclosed |
| WO-2007141473-A1 | N-(BENZOYL)-O- [2- (PYRIDIN- 2 -YLAMINO) ETHYL] -L-TYROSINE DERIVATIVES AND RELATED COMPOUNDS AS A5B1 ANTAGONISTS FOR THE TREATMENT OF SOLID TUMORS | ASTRAZENECA AB (SE) | 2007-12-13 | — | — | WO | disclosed |
| US-20070254916-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | MJALLI ADNAN M | 2007-11-01 | — | — | US | disclosed |
| US-7208601-B2 | Aryl and heteroaryl compounds, compositions, and methods of use | TRANSTECH PHARMA, LLC | 2007-04-24 | — | — | US | disclosed |
| WO-2006093823-A9 | 2- [ ISOQUINOLIN-S - CARBONYL ) AMINO] -PROPIONIC ACID DERIVATIVES AS INHIBITORS OF FACTORS XI AND IX FOR THE TREATMENT OF THROMBOSIS | TRANSTECH PHARMA INC (US) | 2006-11-02 | — | — | WO | disclosed |
| WO-2006093823-A1 | 2- [ ISOQUINOLIN-S - CARBONYL ) AMINO] -PROPIONIC ACID DERIVATIVES AS INHIBITORS OF FACTORS XI AND IX FOR THE TREATMENT OF THROMBOSIS | TRANSTECH PHARMA, INC. (US) | 2006-09-08 | — | — | WO | disclosed |
| US-20050171148-A1 | Aryl and heteroaryl compounds, compositions, methods of use | TRANSTECH PHARMA, LLC | 2005-08-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130096150-A1 | Substituted Azoanthracene Derivatives, Pharmaceutical Compositions, and Methods of Use Thereof | GLP1R, GIPR, GPR119 | KLK5 734/4885CTSS 4434/4885CTSK 4202/4885 |
| US-20110160198-A1 | SUBSTITUTED AZOANTHRACENE DERIVATIVES, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF | GLP1R, GIPR, GPR119 | KLK5 734/4885CTSS 4434/4885CTSK 4202/4885 |
| US-20150148539-A1 | Substituted Azoanthracene Derivatives and Intermediates for Preparation Thereof | GLP1R, GIPR, GPR119 | KLK5 1052/4885CTSS 4204/4885CTSK 3733/4885 |
| US-20090124654-A1 | Aryl and Heteroaryl Compounds, Compositions, Methods of Use | F3, F12, CFH | KLK5 2640/4885CTSS 633/4885CTSK 488/4885 |
| US-20070254916-A1 | Aryl and heteroaryl compounds, compositions, and methods of use | TFPI, F9, F3 | KLK5 578/4885CTSS 502/4885CTSK 376/4885 |
| US-20050171148-A1 | Aryl and heteroaryl compounds, compositions, methods of use | TFPI, F3, F2 | KLK5 620/4885CTSS 478/4885CTSK 372/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.